Plasmapheresis Clinical Trial
Official title:
Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies
Verified date | November 2021 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will collect blood plasma and white blood cells for laboratory research using a procedure called apheresis. Apheresis is a method of collecting larger quantities of certain blood components than can safely be collected through a simple blood draw. Patients 7 years of age and older with a parasitic infection or condition associated with a parasitic infection (i.e., elevated levels of IgE antibodies or of a type of white cell called eosinophils) who are currently enrolled in a NIH clinical research protocol may be eligible for this study. Relatives of patients and normal healthy volunteers will also be enrolled. Candidates will have a medical history, physical examination and blood tests. Individuals weighing less than 25 kilograms (55 pounds) may not participate. Participants will undergo one of the following two apheresis procedures: - Automated pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through a cell separator machine. The plasma (liquid part of the blood) and white cells are extracted, and the red cells are re-infused into the donor through a needle in the other arm. The procedure takes 1 to 2 hours. - Manual pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through the cell separator machine. The red blood cells are separated from the rest of the blood and returned to the donor through the same needle. Usually only one needle stick is required and the procedure takes from 30 to 45 minutes. This method is used only in individuals who weigh less than 35 kg (77 pounds).
Status | Terminated |
Enrollment | 205 |
Est. completion date | November 9, 2021 |
Est. primary completion date | November 9, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years and older |
Eligibility | - INCLUSION CRITERIA: - Enrolled on another LPD protocol. - Weight greater than or equal to 25 kg - Willingness to participate EXCLUSION CRITERIA: - Age less than 7 years - Weight less than 25 kg - Cardiovascular instability - Hct less than 30 - Inadequate venous access - PTT or PT greater than 1.5 normal - Pregnancy - Women who are actively breastfeeding - Other condition which the attending physician or Apheresis Unit staff considers a contraindication to the procedure - For Hetastarch procedure - Hypertension - Evidence of fluid retention |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Boyd A, Ribeiro JM, Nutman TB. Human CD117 (cKit)+ innate lymphoid cells have a discrete transcriptional profile at homeostasis and are expanded during filarial infection. PLoS One. 2014 Sep 25;9(9):e108649. doi: 10.1371/journal.pone.0108649. eCollection 2014. — View Citation
Chatterjee S, Clark CE, Lugli E, Roederer M, Nutman TB. Filarial infection modulates the immune response to Mycobacterium tuberculosis through expansion of CD4+ IL-4 memory T cells. J Immunol. 2015 Mar 15;194(6):2706-14. doi: 10.4049/jimmunol.1402718. Epub 2015 Feb 9. — View Citation
Santiago Hda C, Ribeiro-Gomes FL, Bennuru S, Nutman TB. Helminth infection alters IgE responses to allergens structurally related to parasite proteins. J Immunol. 2015 Jan 1;194(1):93-100. doi: 10.4049/jimmunol.1401638. Epub 2014 Nov 17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To obtain leukocytes,platelets, and plasma from subjects already enrolled on other NIAID/LPD protocols. | Leukocytes, platelets, and plasma will be collected. | Ongoing as this is a method to collect cells from subjects enrolled on other LPD protocols |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03965559 -
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant
|
||
Recruiting |
NCT05562960 -
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
|
N/A | |
Completed |
NCT05815615 -
Plasmapheresis: a Multi-modal Approach
|
N/A | |
Withdrawn |
NCT00203281 -
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
|
Phase 4 | |
Completed |
NCT05004220 -
Effects of Plasmapheresis on Aging Biomarkers
|